Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)

NCT01033760 Phase 3 COMPLETED

The purpose of this trial is to assess the impact of raltegravir, maraviroc, darunavir/r, and Truvada® (emtricitabine/tenofovir) vs. darunavir/r and Truvada® on cell-associated HIV-DNA levels in patients with primary HIV-1 infection.

Details

Lead sponsor	ANRS, Emerging Infectious Diseases
Phase	Phase 3
Status	COMPLETED
Enrolment	90
Start date	2010-04
Completion	2013-12

Conditions

• HIV-1 Infections

Interventions

• raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine
• darunavir; ritonavir; emtricitabine/tenofovir

Primary outcomes

• To compare the 24-month impact of maximized vs. conventional HAART- on HIV reservoirs, as assessed by cell-associated HIV-DNA levels, in patients with acute or primary HIV-1 infection — 24 months

Countries

France